ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cell > STEAP1 > SCCHO-ATP121

CHO/Human STEAP1 Stable Cell Line Development Service

  • Description
    The CHO/Human STEAP1 Stable Cell Line was engineered to express the receptor full length human STEAP1 (Gene ID: 26872), used to mimic cancer target cells. Surface expression of human STEAP1 was confirmed by flow cytometry.
  • Application

    • Useful for cell-based STEAP1 binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    F-12K + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 STEAP1 FACS

Expression analysis of human STEAP1 on CHO/Human STEAP1 Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human STEAP1 Stable Cell Line or negative control cell using anti-human STEAP1 antibody followed by staining with PE anti-human IgG Fc Antibody.

Please contact us if you are interested in related cell pool service.

  • Background
    Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is an integral membrane protein that is highly up-regulated on the cell surface of several human cancers, making it a promising therapeutic target to manage these diseases. It shares sequence homology with three enzymes (STEAP2-STEAP4) that catalyze the DPH-dependent reduction of iron(III). Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 980,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:4 Details
  • Latest Research Phase:Phase 2 Clinical

データシート&ドキュメンテーション

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone